Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mycosan is an over-the-counter topical treatment developed by Serrix for the treatment and prevention of fungal nail infections (onychomycosis) and athlete's foot (tinea pedis). Formulated as a serum or gel, Mycosan contains rye ferment filtrate as its primary active ingredient, alongside pentylene glycol, dimethyl isosorbide, and hydroxyethylcellulose. It is registered as a Class IIa medical device in Europe. Mycosan works through a physical and chemical mechanism of action: it penetrates the nail or skin to form a protective barrier film that inhibits fungal growth, while also acidifying the microenvironment to create unfavorable conditions for dermatophytes (such as Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum). The formulation also helps stabilize and nourish the nail structure to support healthy regrowth.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mycosan.